BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse

Three years with a front-row seat for the development of DKN-01 have failed to persuade BeiGene to pull the trigger on a deal for the oncology drug candidate, leaving Leap Therapeutics looking for a new partner for the anti-DKK1 monoclonal antibody.